Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Financing Cash Flow · Q2 FY2027 · quarter ended Sep 2026

Financing cash flow grows, but more slowly than its trailing trend

Q2 FY2027 financing cash flow of ₹6.32B (cash outflow) rose 18.7% year over year, behind the +123.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 11.2% from the prior quarter.

Context

  • Financing cash flow amounted to 3.8% of revenue in FY2026, down 2.0 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +18.7% toward the trailing-twelve-month pace of +123.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-₹6.32B-11.2% QoQ
Last fiscal yearMar 2026
₹13.4B-29.2% YoY
LTMSep 2026
₹3.08B+123.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.7%——
1 year-29.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

INR · from the cash flow

Latest · FY2026
13.4B INR
Year-over-year change
-29.2%

Financing Cash Flow vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +123.1% is the 2nd highest of 8, against a peer median of -50.8%.
  • Financing cash flow amounts to 0.9% of revenue for RDY, versus a peer median of 10.1%.
RDY Competitors
Financing Cash Flow for RDY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹3.08B INR+123.1%—0.9%
HLNHaleon plcFY2025£2.55B GBP+66.2%—23.2%
VTRSViatris Inc.LTM Jun 2026$1.91B USD-50.8%-30.6%13.0%
BHCBausch Health Companies Inc.LTM Jun 2026$1.1B USD-1097.9%+16.1%10.1%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$401M USD-83.4%+13.1%2.3%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$83.13M USD+1.5%+36.6%11.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$69.63M USD+129.7%-33.4%2.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$21.65M USD-107.9%+24.7%2.3%
Peer median (excluding RDY) —-50.8%+14.6%10.1%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income23.57B45.07B55.68B57.25B45.09B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
Deferred Income Tax8.73B15.3B16.19B19.54B0
Stock-Based Compensation592M397M407M424M0
Change in Working Capital(13.91B)(7.86B)(20.18B)(29.99B)(12.24B)
Accounts Receivables(17.01B)(5.75B)(8.05B)(10.28B)(7.07B)
Inventory(5.33B)(2.65B)(18.45B)(12.75B)(9.05B)
Accounts Payables17.01B0002.94B
Other Working Capital(8.59B)551M6.32B(6.95B)943.83M
Other Non-Cash Items(2.69B)(6.67B)(21.5B)(17.85B)2.12B
Operating Cash Flow28.11B58.88B45.43B46.43B56.65B
Capital Expenditures(19.05B)(18.87B)(27.44B)(34.4B)(24.54B)
Acquisitions (Net)(326M)0(12M)(53.41B)(2.99B)
Purchases of Investments(88.97B)(136.17B)(145.49B)(254.46B)(49.21B)
Sales of Investments77.77B112.81B129.78B279.58B20.63B
Other Investing Activities4.19B(6.68B)(8.16B)(2.28B)1.47B
Investing Cash Flow(26.39B)(41.37B)(40.28B)(58.08B)(70.53B)
Debt Repayment2.74B(20.4B)4.35B23.2B21.31B
Common Stock Issued334M368M805M193M417.73M
Common Stock Repurchased000(1.39B)0
Dividends Paid(4.15B)(4.98B)(6.65B)(6.66B)(7.01B)
Other Financing Activities(1.35B)(1.85B)(2.27B)3.57B(1.33B)
Financing Cash Flow(2.42B)(26.86B)(3.76B)18.91B13.4B
Effect of Forex Changes733M286M(59M)224M(383.41M)
Net Change in Cash32M(9.07B)1.33B7.49B(875.84M)
Free Cash Flow9.06B40.01B18B12.03B32.1B

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.